Kad­mon kicks off 're­al-time' NDA sub­mis­sion with an­oth­er look at 're­mark­able' chron­ic graft-ver­sus-host-dis­ease da­ta

Six months af­ter re­port­ing “knock-your-socks-off kind of re­sults” for its chron­ic graft-ver­sus-host-dis­ease drug from an in­ter­im analy­sis, Kad­mon is back with a fi­nal slate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER